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C3A hepatoma cellsEgg shell membrane (ESM) is a natural and safe food by-product from egg processing whilst
there is little information about the role of ESM as a food component. Effects of dietary ESM
on gene expression in rat liver were investigated through DNA microarray comprehensive
analysis. The expression of smooth muscle-a-actin, which is a marker of hepatic stellate
cells (HSCs) activation, and integrin beta-like 1, decorin, asporin, lumican and collagen type
1 alpha 1, which are components of extracellular matrix (ECM) and involved in the up-reg-
ulation of HSCs activation and fibrosis, was found to be significantly down-regulated after
14 days of ESM treatment. Subsequently, serum obtained from rats given ESM diet also sup-
pressed the expression of COL1A1 and COL1A2 in human hepatoma C3A cells. Our in vivo
and ex vivo findings demonstrate that these gene alterations may contribute to the benefi-
cial effect of ESM partially through down-regulation of c-jun and c-fos signal transduction
thereby blunting HSCs activation and eventually preventing liver fibrosis. These outcomes
not only provide novel information about the functional and nutritional availability of ESM,
but also might contribute to the field of environmental protection.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.h Projects,
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Chicken egg is one of the most popular foods consumed all
over the world. In food manufacturing plants, egg is usually
processed in order to extract the edible part which is com-
posed of yolk and albumen, while large quantities of egg shell
are also generated as an unavoidable by-product in this pro-
cess (Toro, Quijada, Yazdani-Pedram, & Arias, 2007; Yi, Guo,
Zhang, Yu, & Li, 2004). Due to the recent trends in bioresource
recovery and reuse, the utilisation of egg shell has increased
slightly lately. Egg shell can be reused as fertilizer or soil con-
ditioner for farm fields because of its high contents of cal-
cium, magnesium and phosphorus. However, in most cases,
the egg shell and its membrane are still discarded together
into landfills without any pretreatment (Tsai et al., 2006).
These egg wastes have been one of the worst environmental
problems, especially in view of the odour generated from
decomposition.
ESM is a tissue found between the calcified eggshell and
the album of eggs and usually presented as a white to faint
grey powder with a slight characteristic odour. It is made of
thin and highly collagenized fibrous meshworks, which form
layers in contact with the albumen and outer layers touching
the egg shell, with a total thickness of approximately 100 lm
(Pundir, Bhambi, & Chauhan, 2009; Tsai et al., 2006). With this
complex porous structure, ESM contains proteins as major
constituents, mainly collagen (types I, V and X), osteopontin
and sialoprotein, and a small amount of saccharides such
as glycosaminoglycans, including hyaluronic acid and chon-
droitin sulphate-dermatan sulphate copolymer, etc. (Cheng,
Takenaka, Aoki, Murakami, & Aoki, 2009; Fernandez, Passa-
lacqua, Arias, & Arias, 2004; Pundir et al., 2009; Zhang, Wang,
Li, Huang, & Cao, 2010). The semi-permeable membrane
formed by these protein fibres can be bound easily with many
biomolecules, such as enzymes, proteins and antibodies
(Tang, Li, Kang, Zhong, & Zhang, 2009). Due to its large surface
area, porous structure, non-interference with analyte, and
other features, ESM has been used in the past as a membrane
for guided bone regeneration and as a biological dressing to
promote infection-free healing of wounds (Pundir et al.,
2009; Tang et al., 2009; Torres, Troncoso, Piaggio, & Hijar,
2010). So far few applications of ESM have been reported
including matrices for removing various heavy metals and
textile dyes (Ishikawa, Suyama, Arihara, & Itoh, 2002; Shoji,
Miyazaki, Niinou, Kato, & Ishii, 2004; Zhang et al., 2010), sub-
strates for cell culture, platforms for enzyme immobilisation
(Akagawa, Wako, & Suyama, 1999; Choi & Yiu, 2004) and tem-
plates for forming ordered tube networks (Zheng et al., 2010).
Although there are reports on the use of ESM in metallurgy
and bioremediation areas, few information are known about
its role as a food component because of excess of water-insol-
uble collagen (due to a large number of disulphide bond cross-
links) (Cheng et al., 2009; Pundir et al., 2009; Yi et al., 2004) that
ESM applications in food are limited, even though it contains
high amount of amino acids and its safety has been ascer-
tained (Ruff, Endres, Clewell, Szabo, & Schauss, 2012). Never-
theless, collagen can be broken down to single amino acids
and short-chain peptides with digestive enzymes. This way
it can be absorbed in the body and used as an amino acidsource. An ESM containing nutraceutical has been demon-
strated to be clinically effective in the treatment for pain
and stiffness associated with joint and connective tissue dis-
orders, in particular osteoarthritis (Ruff, DeVore, Leu, & Rob-
inson, 2009).
DNA microarray technology has become a powerful diag-
nostic tool indispensable as a part of the development in
genomics and genetic technologies, toxicogenomics, phar-
macogenomics, cell biology, and clinical investigations
addressing prevention and intervention of diseases (Jia,
Takahashi, Saito, & Kato, 2013; Liu-Stratton, Roy, & Sen,
2004). This technology is also receiving increasing attention
to address the beneficial or adverse effects of dietary nutri-
ents or food components on health and disease. This study
was aimed to examine both the effects of dietary ESM on
the gene expression profile in rat liver through a comprehen-
sive analysis using DNA microarray and to validate the
expression of related genes ex vivo using human hepatoma
cell line.
2. Materials and methods
2.1. Preparation of ESM and hydrated ESM powder
ESM was removed from eggshell after cleaning of raw mate-
rial. The stripped ESM was subjected to vacuum drying for
1 h. Neutralized, filtered and desalted ESM was then filtered
through a 70 mesh filter to ensure particle size of 180–
212 lm (Kewpie Corporation, Tokyo, Japan). The amino acid
composition (mg/g) of ESM is as follows: 42 Lys,19 His, 30
Arg, 13 Trp, 66 Asp, 47 Thr, 26 Ser, 108 Glu, 64 Pro, 49 Gly, 33
Ala, 129 Cys, 38 Val, 36 Met, 31 Ile, 47 Leu, 18 Tyr and 19
Phe. Hydrated ESM powder (HEM), which is easy to dissolve
to at least 40% (w/v) in ultra-pure water at room temperature,
was obtained by hydrolyzing ESM in alkaline water-miscible
organic solvent (Ohto-Fujita et al., 2011). HEM contains the
following amino acids (mg/g): 59 Lys, 28 His, 21 Arg, 22 Trp,
50 Asp, 45 Thr, 49 Ser, 105 Glu, 66 Pro, 79 Gly, 45 Ala, 34 Cys,
65 Val, 40 Met, 41 Ile, 54 Leu, 16 Tyr and 17 Phe.
2.2. Animals and diets
MaleWistar rats of 6 weeks obtained from Charles River Japan
(Tokyo, Japan) were housed individually in animal cages in a
room with controlled temperature (22 ± 2 C), humidity
(50 ± 10%) and lighting (lights on from 8:00 to 20:00 h), and
fed a commercial non-purified diet (Type NMF, Oriental Yeast
Co., Tokyo, Japan). After one week of acclimatization, animals
were divided into three groups (N = 6) with equal means of
body weights and fed with either basic diet (Control), basic
diet with 10 g kg1 ESM powder (ESM group), or with 10 g kg1
HEM powder (HEM group) for 14 days. The basal composition
of the purified experimental diet was (in g/kg): casein, 140;
soybean oil, 50; cellulose, 120; mineral mixture, 40; vitamin
mixture, 10; methionine, 2 and b-cornstarch to 1 kg. ESM
was added to the diets in place of b-cornstarch. Feeding time
was from 15:00 to 9:00, with access to tap water ad libitum.
At the end of the experimental period, after 7-h depriva-
tion of food, all rats were anesthetized with Nembutal and
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tained by centrifugation of blood at 1000g for 15 min at 4 C.
The livers were excised, rinsed with phosphate-buffered sal-
ine (pH 7.0) and weighed. The liver samples were stored at
80 C until they were analyzed. This study was approved
by the Institutional Animal Care and Use Committee of The
University of Tokyo, and the animals were treated in accor-
dance with the guidelines.
2.3. Biochemical assay
The plasma levels of triglyceride (TG), total cholesterol (TC),
high-density lipoprotein cholesterol (HDL), low-density lipo-
protein cholesterol (LDL) and non-esterified fatty acid (NEFA)
were determined enzymatically using commercial kits (Wako
Pure Chemical Co., Tokyo, Japan) according to the manufac-
turer’s protocol.
2.4. Total RNA extraction and quality verification
Total RNA from frozen liver was isolated using TRIzol
(Invitrogen, Tokyo, Japan) according to the manufacturer’s
instructions. Dry RNA pellets were resolubilized in 50 ll of
RNase-free water. The concentration was determined from
the optical density at 260 nm on a NanoDrop ND-1000 spec-
trophotometer (Thermo Scientific, Wilmington, DE, USA),
and the purity was ascertained from the value (between 1.9
and 2.1) of the A260/A280 ratio.
2.5. cDNA microarray analysis
Affymetrix GeneChip Rat Genome 230 2.0 Array containing
over 30,000 gene probe sets were used for genome-wide
expression profiling. A complete list of the genes on this array
was provided by themanufacturer. The arrays were processed
according to the standard Affymetrix protocol (GeneChip
Expression Analysis Technical Manual) established by
Affymetrix (Santa Clara, CA, USA). The RNA probes were
made by pooling an identical amount of RNA samples ob-
tained from individual rats. Briefly, the pooled total RNA
was reverse transcribed into double stranded cDNA using
the Affymetrix GeneChip 3 0 IVT Express kit. Aliquots of the la-
beled DNA were combined with the hybridization solution at
45 C for 16 h. After washing and staining, the arrays were
scanned using the Affymetrix GeneChip Scanner 3000.
2.6. Mapping and ingenuity pathway functional analysis
The scanned images were analyzed with the GeneChip Oper-
ating Software (GCOS version 1.1, Affymetrix) for gene expres-
sion ratios between the control and ESM or HEM groups. To
build the gene list for subsequent analyses, differentially ex-
pressed genes were selected according to the following strin-
gent filtering criteria. First, absent or marginally expressed
genes as well as ‘no change’, ‘marginal increase’ and ‘mar-
ginal decrease’ probe sets comparisons were excluded. Next,
the average values of signal intensity greater than 100 were
chosen. Ultimately, a list containing the informative expres-
sion data was built. The fold-change value was calculated
from the signal log ratio. Genes showing expression ratiosbetween treatments of more than 1.5-fold or less than
0.667-fold were then selected. Molecular interactions between
genes were mapped using the Pathway Explorer function of
Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com/).
2.7. Preparation of serum from ESM-treated rats (ex vivo
assay)
After 3 days of acclimatization, 7 week old male Wistar rats
were divided into two groups (N = 4) with equal mean body
weights. Normal Control group (NC) was fed AIN-93G diet
whilst ESM group was fed AIN-93G diet supplemented with
20 g kg1 of ESM powder adjusted to 1 kg using b-cornstarch.
Rats were subjected to each diet and drinking water ad libitum
for 4 weeks. At time of dissection, rats were deeply anaesthe-
tized following which blood was collected via cardiac punc-
ture. Serum was obtained by centrifugation at 3000g for
15 min and sterilized by filtration using a 0.22 lm syringe-dri-
ven filter units (Millipore; Billerica, MA, USA). Pooled sera
from individual rats were stored at 80 C.
2.8. Culture of C3A hepatoma cells
Human C3A hepatoma cells (CRL-12461, ATCC, Manassas, VA,
USA) were plated onto the inner wells of 12-well tissue cul-
ture plate at a density of 3 · 105 cells per well and cultured
in the respective media: Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma–Aldrich, St. Louis, MO, USA) containing 1%
penicillin/streptomycin, supplemented with either 2% fetal
bovine serum (FBS), or 2% rat serum from NC group (NCS) or
2% rat serum from ESM group (ESMS). All cultures were kept
at 37 C in a humidified atmosphere incubator with 5% CO2
for 48 h and then harvested. Cytotoxicity under all incubation
conditions was assessed by lactate dehydrogenase (LDH) leak-
age into the culture medium with using a LDH-Cytotoxic Test
kit (Wako Pure Chemical Industries, Tokyo, Japan). Harvested
cells were stored at 20 C.
2.9. Total RNA extraction and real-time reverse
transcription polymerase chain reaction
TotalRNAfromharvestedcellswere isolatedbyusingTRIzol re-
agent as described in Section 2.4. After RNA concentration
measurement andquality assessment, 1 lg of RNAwas reverse
transcribedat37 Cusing thePrimeScriptRTEnzyme(Takara,
Shiga, Otsu, Japan). Real-Time Reverse Transcription Polymer-
aseChainReaction (RT-PCR)wasperformedusing the real-time
PCRdetection system (TakaraBio,Madison,WI,USA) in2%FBS,
2%NCSand 2%ESMSgroup cells to detect the expressionof the
following genes: Collagen, type I, alpha 1, (COL1A1); Tissue inhibi-
tor of metalloproteinase-1, (TIMP1); Insulin-like growth factor bind-
ing protein 1, (IGFBP1) and Transforming growth factor beta 1,
(TGFB1). Finalmixture (12.5 lL) for RT-PCR consisted of 1· SYBR
Premix Ex TaqMix (Takara), 0.4 lMof primers (forward and re-
verse) and 1 lL cDNA. Primerswere designedwith aweb appli-
cation (PRIMER3), and their sequences are as shown as follows:
COL1A1-F: AACAGCCGCTTCACCTACAG; COL1A1-R: TGGGA
TGGAGGGAGTTTACA; TIMP1-F: CTGTTGTTGCTGTGGCTGAT;
TIMPT-R: CATCCCCTAAGGCTTGGAAC; IGFBP1-F: AGGCTCTC-
CATGTCACCAAC; IGFB1-R: GAGACCCAGGGATCCTCTTC; TGFB1-
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TAG; b-actin-F: GCGTGACATTAAGGAGAAG and b-actin-R:
GAAGGAAGGCTGGAAGAG. The relative amounts of mRNA
were normalized to b-actin expression levels in each sample,
and the datawere presented as the fold changes of normalized
mRNA amounts to those of the FBS group.
2.10. Statistical analysis
The results of the experiment are expressed as means ± SD.
Data were analyzed with a one-way ANOVA, and the Tukey
test and Dunnett test were used in animal experiment and
ex vivo assay, respectively, to evaluate the significant differ-
ences of the means at the level of P < 0.05.
3. Results
3.1. Effects of ESM and HEM on growth and plasma lipids
in rats
Changes in body weight and biochemical parameters are
listed in Table 1. No change was found in body weight, food
intake, liver weight (data not shown), plasma LDL and NEFA
among the three groups. The plasma TC, TG and HDL levels
in both ESM and HEM groups were slightly increased without
statistical significance compared to those of the control
group.
3.2. Differentially expressed genes in liver
Two pairs of comparisons were performed to identify hepatic
gene expression associated with ESM and HEM supplementa-
tion on day 14. Among the total probes on the Rat Genome 230
2.0 Array used in this study, 16136 and 16168 genes (over 50%)
were identified as present in liver of rats fed with ESM and
HEM, respectively. The numbers of genes with change more
than 1.5-fold in their expression levels compared to the con-
trols were 16 genes (up-regulated) and 17 genes (down-regu-
lated) in ESM group, and 16 genes (up-regulated) and 39
genes (down-regulated) in HEM group. These differentially ex-
pressed genes are further detailed in Table 2.
3.3. Gene expression related to hepatic stellate cells
activation
Treatment with ESM for 14 days induced a significant down-
regulation in the expression of integrin beta-like 1 (Itgbl1),Table 1 – Changes in body weight and plasma lipids in ESM a
Control
Body weight 286.5 ± 14.02
TG (mg/dL) 200.2 ± 42.46
TC (mg/dL) 73.0 ± 2.00
LDL (mg/dL) 8.3 ± 1.63
HDL (mg/dL) 46.0 ± 2.76
NEFA (Eq/L) 0.7 ± 0.12smooth muscle-a-actin (a-Sma), decorin, asporin, lumican
and collagen type 1 alpha 1 (Col1a1) (Table 2), which are com-
ponents of extracellular matrix (ECM) and have already been
reported to be up-regulated in activated hepatic stellate cells
(HSCs) and involved in fibrosis. Itgbl1 is a member of the inte-
grin family and works as a fibronectin or collagen receptor in-
volved in the production of type I collagen in HSCs (Sekiya,
Ogawa, Yoshizato, Ikeda, & Kawada, 2011). The a-SMA is an
intracellular microfilament protein and a marker of the acti-
vated phenotype of HSCs (Ja´rmay et al., 2000; Lewindon
et al., 2002). Decorin is a small leucine-rich extracellular ma-
trix proteoglycan (SLRPs), which is mainly involved in the reg-
ulation of formation and organization of collagen fibrils,
modulation of the activity of growth factors such as trans-
forming growth factor b (TGF-b), and regulation of cellular
growth (Ja´rmay et al., 2000; Shi et al., 2006). Asporin is also a
member of SLRPs family of TGF-b binding proteins (Kaliakat-
sos et al., 2006). Col1a1, a main component of ECM, is secreted
by activated HSCs, and its deposition is responsible for the
onset of fibrosis.
Furthermore, the expression of basic helix-loop-helix do-
main containing, class B2 (Bhlhb2) and fibroblast growth factor
21 (Fgf21) was significantly suppressed, whereas the expres-
sion of a lipid metabolism enzyme, cytochrome P450, family
7, subfamily A, polypeptide 1 (Cyp7a1) was significantly up-
regulated in rats treated with ESM. BHLHB2 is a bHLH tran-
scription factor that is frequently differentially expressed in
several malignancies, such as colon, breast, stomach, central
nervous system and non-small-cell lung cancers (Wang et al.,
2010). FGF21 has been shown to play a critical role in glucose
and lipid metabolism in animal models (Dushay et al., 2010;
Naderali, Wong, & Hussain, 2009). Finally, CYP7A1 is a pivotal
enzyme in lipid cholesterol metabolism and is expressed
mainly in liver (Chiang, 2003).3.4. Expression of c-fos and c-jun
The expression of c-fos and c-jun were investigated, as they
form the transcription factor AP-1 complex and are located
downstream of signal kinases, such as focal adhesion ki-
nase (FAK), extracellular signal-regulated kinase (ERK) and
phosphatidyl-inositol 3-kinase/agammaglobulinemia tyro-
sine kinase (PI3K/ATK). As shown in Fig. 1, expression of
c-fos were reduced by 0.41 and 0.76 folds and c-jun expres-
sion by 0.66 and 0.87 folds with HEM and ESM treatment,
respectively.nd HEM fed rats.
ESM HEM
282.1 ± 9.37 288.8 ± 13.24
193.5 ± 66.19 220.2 ± 41.51
78.5 ± 7.31 79.0 ± 8.29
9.0 ± 2.68 8.3 ± 2.73
51.0 ± 5.73 50.8 ± 8.38
0.7 ± 0.20 0.7 ± 0.13
Table 2 – Differentially expressed genes in rat liver.
Gene ID Symbol Name Fold change
Upregulated genes
ESM
Rn.20571 Bcl6 B-cell leukemia/lymphoma 6 2.64
Rn.1950 Hspa1a /// Hspa1b Heat shock 70 kDa protein 1A /// heat shock 70 kDa protein 1B 2.14
Rn.144946 Rrm2 Ribonucleotide reductase M2 2.14
Rn.24858 Cisd2 CDGSH iron sulfur domain 2 1.87
Rn.97779 Pnpla3 Patatin-like phospholipase domain containing 3 1.87
Rn.3412 RGD1565095 Similar to hypothetical protein MGC52110 1.87
Rn.10737 Cyp7a1 Cytochrome P450, family 7, subfamily a, polypeptide 1 1.74
Rn.107220 Cdkn3 Cyclin-dependent kinase inhibitor 3 1.62
Rn.6934 Cdc2 Cell division cycle 2, G1 to S and G2 to M 1.52
Rn.9862 Pbsn Probasin 1.52
Rn.1416 Sqrdl Sulfide quinone reductase-like (yeast) 1.52
HEM
Rn.20571 Bcl6 B-cell leukemia/lymphoma 6 3.48
Rn.24858 Cisd2 CDGSH iron sulfur domain 2 2.30
Rn.19898 Cyp26b1 Cytochrome P450, family 26, subfamily b, polypeptide 1 2.00
Rn.1416 Sqrdl Sulfide quinone reductase-like (yeast) 2.00
Rn.97779 Pnpla3 Patatin-like phospholipase domain containing 3 1.87
Rn.67791 Fign_predicted Fidgetin (predicted) 1.74
Rn.3412 RGD1565095 Similar to hypothetical protein MGC52110 1.74
Rn.76726 Cdh17 Cadherin 17 1.62
Rn.10907 Cxcl1 Chemokine (C-X-C motif) ligand 1 1.62
Rn.35367 Acsm5 Acyl-CoA synthetase medium-chain family member 5 1.52
Rn.46320 Cib2 Calcium and integrin binding family member 2 1.52
Rn.32153 Sall1 Sal-like 1 (Drosophila) 1.52
Downregulated genes
ESM
Rn.12893 Itgbl1 Integrin beta-like 1 0.54
Rn.195319 a-SMA Smooth muscle alpha-actin 0.57
Rn.162560 Fam134b Family with sequence similarity 134, member B 0.57
Rn.81055 Bhlhb2 Basic helix-loop-helix domain containing, class B2 0.57
Rn.81231 Fgf21 Fibroblast growth factor 21 0.57
Rn.106103 Dcn Decorin 0.62
Rn.103770 Gsn Gelsolin 0.62
Rn.3087 Lum Lumican 0.66
Rn.32517 Alas2 Aminolevulinic acid synthase 2 0.66
Rn.160633 Aspn Asporin 0.66
Rn.2953 Col1a1 Collagen type 1 alpha 1 0.66
HEM
Rn.48812 Onecut1 One cut homebox 1 0.33
Rn.48812 Onecut1 One cut homebox 1 0.38
Rn.14523 Cish Cytokine inducible SH2-containing protein 0.38
Rn.103750 Fos FBJ murine osteosarcoma viral oncogene homolog 0.41
Rn.19440 Slc25a30 Solute carrier family 25, member 30 0.44
Rn.19440 Slc25a30 Solute carrier family 25, member 30 0.50
Rn.44452 Gpd1 Glycerol-3-phosphate dehydrogenase 1 (soluble) 0.57
Rn.81231 Fgf21 Fibroblast growth factor 21 0.57
Rn.144632 Usp2 Ubiquitin specific peptidase 2 0.57
Rn.10725 Mafb V-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) 0.57
Rn.6839 Tnrc6a Trinucleotide repeat containing 6a 0.62
Rn.10470 Foxa1 Forkhead box A1 0.62
Rn.98260 Dusp1 Dual specificity phosphatase 1 0.66
Rn.74258 Abcg5 ATP-binding cassette, sub-family G (WHITE), member 5 0.66
Rn.22325 Trib3 Tribbles homolog 3 (Drosophila) 0.66
Rn.64258 Ammecr1l AMME chromosomal region gene 1-like 0.66
Rn.81055 Bhlhb2 Basic helix-loop-helix domain containing, class B2 0.66
Rn.8672 Eiih Hepatic protein EIIH 0.66
Rn.10949 Foxa3 Forkhead box A3 0.66
Rn.15806 Junb Jun-B oncogene 0.66
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Fig. 1 – Ingenuity pathways analysis of c-fos and c-jun down-regulation with ESM and HEM treatment. Green indicates down-
regulation, with the more intense color indicating a greater change. Numbers under each node are Log ratio. Genes in
uncolored nodes were not identified as differentially expressed in this experiment. Jun oncogene (Jun), SMAD family member
7 (Smad7), CCAAT/enhancer binding protein alpha (Cebpa), hematopoietically expressed homeobox (Hhex), FBJ murine
osteosarcoma viral oncogene homolog (Fos), early growth response 1 (Egr1), Jun-B oncogene (Junb), ubiquitin-conjugating
enzyme E2O (Ube2o), DNA-damage inducible transcript 3 (Ddit3), dual specificity phosphatase 1 (Dusp1), forkhead box A1
(Foxa1), alpha-2-macroglobulin (A2m), aminolevulinic acid synthase 1 (Alas1), collagen type I alpha 2 (Col1a2), v-maf
musculoaponeurotic fibrosarcoma oncogene family, protein B (Mafb).
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LDH activities were 62.42 ± 6.60 and 63.52 ± 5.58% in NCS and
ESMS group, respectively, as compared to FBS at 100%. This
showed no evidence of cell toxicity with any of the NCS and
ESMS used.
3.6. Effect of ESM treated rat serum on gene expression of
C3A cells in culture
ESMS suppressed the mRNA expression of COL1A1 and
COL1A2 (P < 0.05, Fig. 2), even though there was no significant
effect on the expression of TIMP1, TGFb1 and IGFBP1 as com-
pared to NCS (data not shown).
4. Discussion
Using DNA microarray analysis to obtain nutrigenomic infor-
mation, we found that ESM treatment markedly down-regu-
lated the expression of Col1a1, a-Sma, Itgbl1, decorin, asporin
and lumican, which are key genes involved in the activation
of HSCs. Activated HSCs trans-differentiate into myofibro-
blast-like cells, which are proliferative cells that lose vitamin
A, express a-SMA, and secrete profibrogenic mediators and
ECM components, including collagen, proteoglycans and
adhesive glycoproteins (Sekiya et al., 2011; Shi et al., 2006).
It has been demonstrated that an increase in the number of
a-SMA-expressing HSCs occurs in several pathologic condi-
tions associated with fibrosis (Ja´rmay et al., 2000). In the pres-
ent study, the expression of a-Sma, the marker of HSCsactivation, was remarkably decreased by ESM, indicating that
ESM may blunt HSCs activation.
It is known that an increase in collagen synthesis and
deposition is the main cause of fibrosis and cirrhosis. Itgbl1
is reported to be involved in the production of type I collagen
and monocyte chemotactic protein-1 in HSCs (Sekiya et al.,
2011). Decorin can also regulate collagen fibrillogenesis and
modulate growth factor activity, and the level of its mRNA
expression increases in rat liver during fibrosis and cirrhosis
(Li, McFarland, & Velleman, 2008; Shi et al., 2006) From
our microarray data, ESM treatment was found to be followed
by a significant decrease in Colla1, Itgbl1 and decorin expres-
sion, demonstrating that ESM treatment is capable of pre-
venting fibrogenesis. In addition to collagen, elastic fibers,
noncollagenous glycoproteins and various proteoglycans, as
components of ECM, also contribute to the chronic liver dam-
age(Chang et al., 2013), the formation of fibrosis and cirrhosis,
and eventually hepatocellular carcinoma(Hwang et al., 2013).
The inhibition of HSCs activation is regarded as one of the
promising ways to prevent fibrogenesis. Down-regulated
expression of asporin and lumican in this study additively
contributed to suppress fibrosis with ESM. These results sug-
gested that ESM affects activation of HSCs and could be a can-
didate molecule for suppressing their activation and the
consequent liver fibrosis.
TGF-b1 is known as a key regulator of collagen production
and fibrosis. Decorin plays an important role in fibrogenesis
by regulating TGF-b1 and directly modulating the degradation
of ECM from activated HSCs (Ja´rmay et al., 2000; Shi et al.,
2006). However, in this study the mRNA expression level of
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Fig. 2 – Gene expression of COL1A1 and COL1A2 of C3A cell
lines using ESM given rat serum. C3A cell line was cultured
in DMEM supplemented with either 2% fetal bovine serum
(FBS), or 2% rat sera from NC group (NCS) or 2% rat sera from
ESM group (ESMS) for 48 h at 37 C with 5% CO2. Gene
expression was analyzed by RT-PCR. Data are expressed as
means and SD of triplicate wells. Significant differences
between NCS and ESMS as determined by Dunnett test are
indicated as P < 0.05.
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sons not fully understood. Similarly, matrix metalloprotein-
ases (Mmps) family, a major group of enzymes responsible
for ECM degradation, and tissue inhibitors of MMPs (Timps),
specific inhibitors of MMPs (Shi et al., 2006), showed no al-
tered expression, suggesting that ESM may be involved in
ECM synthesis networks rather than ECM degradation
pathway.
To elucidate the complete relationship of the underlying
mechanisms, we also investigated in which way ESM func-
tioned in blocking HSCs activation. Intracellular signaling
molecules such as FAK, ERK and PI3K/Akt are known to be
key mediators or mediated by collagen (Krepinsky, 2005;
Son, Hines, Lindquist, Schrum, & Rippe, 2009), Itgbl1 (Shioj-
ima, 2002), decorin (Schonherr, 2001). Thus their down-regu-
lation by ESM may affect down- or upstream signaling,
resulting in the inhibition of both activation and prolifera-tion of HSCs. To verify this, we investigated the mRNA
expression of c-fos and c-jun, which form the transcription
factor AP-1 complex and are located downstream of these
signal kinases. Expression of c-fos and c-jun were also re-
duced with ESM and HEM treatment. As AP-1 is known to
be one of the key transcription factors for the initiation of
HSCs activation (Poulos et al., 1997), this result indicates
that c-fos and c-jun were down-regulated at least partially
by ESM.
Liver injury, such as fatty liver disease, either alcoholic or
nonalcoholic (NAFLD), generally begins as hepatic steatosis,
and, if the cause persists, this steatosis invariably progresses
to steatohepatitis, cirrhosis and DM liver cancer (Reddy & Rao,
2006). Hepatic steatosis represents an excessive accumulation
of fat that surpasses the energy combustion capability of the
fatty acid oxidation systems. One of the lipid cholesterol met-
abolic outputs in the liver is conversion of cholesterol to bile
acids, where CYP7A1 is the rate-limiting enzyme in this con-
version (Kwok et al., 2013; Wu et al., 2013). Our study showed
that the gene expression of Cyp7a1 was significantly up-regu-
lated in ESM-fed rats, indicating that ESM may have a choles-
terol-lowering effect that can suppress liver injury, and
eventually liver fibrosis. Even no change was found in plasma
total cholesterol, we speculate that it requires a longer period
before this phenotype is expressed clearly. In addition, it is re-
ported that Fgf21 mRNA expression was significantly elevated
in NAFLD, which correlated with a substantial increase in cir-
culating FGF21 (Mai et al., 2011). Not only in liver injury, FGF21
levels also increased in obesity, insulin resistance, impaired
glucose tolerance, and hypertriglyceridemia (Dushay et al.,
2010; Naderali et al., 2009). Therefore, the down-regulated
expression of Fgf21 with ESM treatment suggests a potential
role in lipid metabolism regulation and in the pathogenesis
of insulin resistance, always a kind of complication of hepatic
steatosis. FGF21 is reported to be regulated by peroxisome
proliferatoractivated receptor-a (PPARa) (Li et al., 2010). How-
ever, since PPARa level in this study was unaffected, further
studies are required to demonstrate the role of ESM as a po-
tent metabolic regulator with effects on lipid metabolism
and hepatic steatosis.
To confirm the bioavailability of ESM of its inhibitory effect
on the fibrosis, we also examined the effect of ESM on ECM re-
lated gene expression using an ex vivo test. Serum obtained
from dietary ESM given rats suppressed expression of COL1A1
and COL1A2, which suggests that ESM was absorbed from the
gastrointestinal tract, and that ESM or its metabolite(s) in the
blood suppressed expression and production of collagen of
C3A cells. These results also validated that the inhibitory
properties of ESM or its metabolites are available both
in vivo and ex vivo.
Nutrigenomics, an innovative scientific study using micro-
array, along with rapidly developing analytical and informa-
tion technologies, can provide a basis to understand the
health consequences with specific bioactive food components
and how they harmonize to influence individual phenotypes
(Trujillo, Davis, & Milner, 2006). These information may be
used to convey the experience to scientific data and to design
future research, ultimately leading to promotion of human
health and disease prevention. In the present study, using
nutrigenomics analysis along with an ex vivo validation, we
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health, especially with regards to liver fibrosis and cirrhosis.
Taking into account that cirrhosis is a currently prevalent dis-
ease worldwide, we consider it important to study the poten-
tial health benefits of ESM as a possible new effective and safe
therapeutic option in the prevention of cirrohsis.
As ESM is a relatively new nutraceutical, hereby we would
like to provide basic information regarding its composition
and safety to encourage widespread consumption of this nat-
ural product. This protein is stable in the presence of acid,
alkaine and protease and is only slightly soluble in water
due to the amino acids of the protein containing a significant
amount of cysteine and desmosine which may form solid
molecular bonds between the protein molecules. 100 g of
ESM contains approximately 401 kcal calories, 92.4 g protein,
0.2 g fat, 0 g carbohydrate, 23.7 mg sodium, 5.7 g water and
1.7 g ash. The amino acid composition (mg/g) of ESM is as fol-
lows: 42 Lys,19 His,30 Arg, 13 Trp, 66 Asp, 47 Thr, 26 Ser, 108
Glu, 64 Pro, 49 Gly, 33 Ala, Cys 129, Val 38, Met 36, Ile 31, Leu
47, 18 Tyr and 19 Phe. Inorganic components of ESM include
approximately 11 lg/g phosphrous, 12–30 lg/g magnesium,
21–35 lg/g potassium, 15–18 lg/g magnesium, 11–20 lg/g so-
dium, 1–3 lg/g zinc, 1–3 lg/g manganese, 5–10 lg/g iron, 0.1–
0.9 lg/g copper, 0.1–0.5 lg/g boron and 1–6 lg/g aluminum
(Kewpie Corporation, http://www.kewpie.co.jp/english/fc/
imgs/02/em.pdf). Other components of ESM include desmo-
sine and isodesmosine, ovotransferrin, lysyl oxidase, lyso-
some and b-N-acetylglucosaminidase (Ahlborn, Clare,
Sheldon, & Kelly, 2006; Akagawa et al., 1999; Gautron, Hincke,
Panheleux, Garcia-Ruiz, & Boldicke, 2001; Hincke, Gautron,
Panheleux, Garcia-Ruiz, & McKee, 2000; Starcher, GS., & K.,
1980). None of the reported constituents of eggshell mem-
brane have been previously reported to be substaintially cyto-
toxic individually (Anderson, Nicolosi, & Borzelleca, 2005;
Necas, Bartosikova, Brauner, & Kolar, 2008). In addition, lack
of cytotoxicity in whole ESM has been observed in human-de-
rived epidermal keratinocytes. ESM also plays a vital role in
the development of fetus to fowl, as such, there would be
no reason to expect ESM to be mutagenic. In vitro studies as
well as clinical studies have shown that patients did not suf-
fer from toxicity when subjected to acute or subchronic re-
peated oral toxicological evaluation (Ruff et al., 2012).
As ESM is has been validated to be a safe and natural food
by-product in egg processing, the current study not only pro-
vides information about the functional and nutritional avail-
ability of ESM, but also contributes to the field of
environmental protection, which is an increasing demand
in society. To our knowledge this is the first study that focuses
on ESM as a by-product and its potential role as a food ingre-
dient in the prevention of liver fibrosis. It is important to dem-
onstrate and share to the public the safeness and
effectiveness of this novel natural food product as well as
its therapeutical benefits. On the basis of the nutrigenomic
information obtained in this study by using DNA microarray,
further functional studies will be carried out to elucidate this
new protective function of ESM using liver injury or cirrhosis
rat model. In this way, even during its infancy in science,
nutrigenomic approaches can surely provide many valuable
new insights for health and will demand greater attention
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